Richard Gray on a Longer Duration of Tamoxifen

Name: Richard Gray on a Longer Duration of Tamoxifen
Uploaded: 2013-06-02T12:28:36.000Z
Description: Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

June 2, 2013

Richard G. Gray, MA, MSc

Video

Conference|ASCO Annual Meeting

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Richard G. Gray, MA, MSc, a professor of medical statistics at the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Overall, Gray notes, fewer breast cancer recurrences were seen in the 10-year tamoxifen group than in the 5-year group. In all, women who continue tamoxifen treatment had a 25 percent lower recurrence rate and a 23 percent lower breast cancer mortality rate.